Paul A. Frohna, MD, PhD, PharmD

Dr. Frohna is a physician-scientist with expertise in translational medicine and clinical research that has been applied to the development of novel small molecules, biologics, peptides, and cell therapies in immuno-oncology, immunology, and neurodegenerative diseases for over 20 years. Since 2019, serves as the CMO of ImCheck Therapeutics where he oversees all R&D activities for the pipeline of butyrophilin-targeted mAbs, including the g9d2 T cell-activating antibody ICT01 that is in Phase II trials in solid and hematologic malignancies.

Previously, Dr. Frohna served in executive and senior clinical development roles at Bioniz Therapeutics, Receptos, and Genentech. Dr. Frohna trained in internal medicine after graduating with an MD from Georgetown University (USA), a PhD in Pharmacology from PENN (USA), and a Pharmacy Degree from the University of Texas at Austin (USA).